Neumora Therapeutics, Inc. Common Stock
Neumora Therapeutics, Inc. Common Stock（NMRA）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
nmra · 股价预测 · 9 位分析师（近3月）· FMP · 更新于 2026年6月8日
分析师评级与共识
基于过去 3 个月内 9 位华尔街分析师
Buy
9 位分析师
共识
评级分布
12 个月目标价
High
$8.00
Consensus
$7.00
+332.1% upside
Low
$6.00
Median: $7 · Last Close: $1.62
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$7.00
332.1% upside
High Target
$8
393.8%
Low Target
$6
270.4%
Current Price
$1.62
as of today
Based on analyst price targets, the NMRA stock price prediction for the next 12 months ranges from $6 to $8. The consensus NMRA price forecast of $7.00 implies 332.1% upside from the current price of $1.62.
短期股价预测
Low Activity算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $1.57 | ↓ 3.19% |
1-day model range: $1.53–$1.61. Peak: $1.61 (-3.19%).
长期股价预测
年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | -50.0% |
| 2028 | — | -63.7% |
| 2029 | — | -69.2% |
| 2030 | — | -71.8% |
| 2031 | — | -73.1% |
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · NMRA · Jun 8, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-31 | Guggenheim | Maintains | Buy→Buy |
| 2026-03-31 | Needham | Maintains | Buy→Buy |
| 2026-02-17 | William Blair | Upgrade ↑ | Market Perform→Outperform |
| 2025-12-01 | RBC Capital | Upgrade ↑ | Sector Perform→Outperform |
| 2025-11-17 | Stifel | Maintains | Hold→Hold |
| 2025-10-28 | Needham | Maintains | Buy→Buy |
| 2025-10-27 | Guggenheim | Upgrade ↑ | Neutral→Buy |
| 2025-09-16 | JP Morgan | Downgrade ↓ | Neutral→Underweight |
| 2025-07-16 | Mizuho | Maintains | Outperform→Outperform |
| 2025-05-13 | Needham | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Neumora Therapeutics, Inc. Common Stock (NMRA) stock. Of the recent 35 rating actions, 3 were upgrades and 5 were downgrades. 9 analysts currently cover NMRA.
分析师推荐趋势
NMRA analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 2 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$1M
↓ 99.1% YoY
Revenue Next Year
$6M
↑ 842.5% YoY
EPS This Year
$-0.96
EPS Next Year
$-0.89
↓ 7.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast NMRA EPS of $-0.96 for the current fiscal year, based on estimates from 7 analysts. The NMRA revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
NMRA 股价预测由两类独立数据源支撑：来自 9 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。NMRA 的共识目标价为 $7.00（+332.1% 上行空间），分析师共识为 Buy。
NMRA 的短期预测（明日）为 $1.57（-3.19%）。 NMRA 对 2030 年的预测区间为 $0–$1。
Neumora Therapeutics, Inc. Common Stock 在 NASDAQ 上市，代码 NMRA。NMRA 在 2027 年的整体展望偏积极，在覆盖分析师中约 67% 对应 Buy 共识。
常见问题
NMRA 预测 · 8 个问题根据 9 位华尔街分析师，NMRA 的 12 个月平均目标价为 $7.00，最高 $8.00、最低 $6.00。若有图表，中位目标价可在上方查看。相对当前价 $1.62，隐含约 +332.1% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.